According to the ABC, Danish biopharmaceutical company Novo Nordisk announced on the 10th that it will lay off 9,000 employees in a new round of global restructuring, accounting for about 11% of the company's total employees.
As the market competition for weight loss drugs is becoming increasingly fierce, Novo Nordisk aims to streamline the organizational structure and improve decision-making speed. Through the new restructuring plan, Novo Nordisk expects to save 8 billion Danish kronor (about 8.9 billion yuan) by the end of 2026, and the savings will be used for businesses in the fields of diabetes and obesity, including R&D.
Novo Nordisk currently has about 78,400 employees worldwide, and about 5,000 of the layoffs are located in Denmark. The company said the layoffs will be launched immediately and affected employees will receive notifications in the coming months in accordance with local labor regulations.
Source: CCTV Finance
